<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82443">
  <stage>Registered</stage>
  <submitdate>26/11/2007</submitdate>
  <approvaldate>28/11/2007</approvaldate>
  <actrnumber>ACTRN12607000610437</actrnumber>
  <trial_identification>
    <studytitle>The bone effects of pioglitazone</studytitle>
    <scientifictitle>A randomized controlled trial of the effects of pioglitazone on bone density and bone turnover in type 2 diabetes mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes mellitus</healthcondition>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pioglitazone 30mg per oral daily for 12 months</interventions>
    <comparator>Placebo, sugar pill, per oral</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in lumbar spine bone density, measured by dual energy xray absorptiometry</outcome>
      <timepoint>1 year after randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total hip bone density, measured by dual energy xray absorptiometry</outcome>
      <timepoint>1 year after randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chnage in biochemical markers of bone formation, assayed in serum</outcome>
      <timepoint>1 year after randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Type 2 diabetes mellitus (T2DM), as defined by fasting blood glucose &gt; 7mmol/L and/or serum glucose &gt; 11mmol/L 2h after ingesting 75g oral glucose.
- impaired glucose tolerance, as defined by fasting blood glucose &lt; 6-7 mmol/L and/or serum glucose 7.8-11mmol/L 2h after ingesting 75g oral glucose</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Medical Conditions
- subjects with type 2 diabetes mellitus (T2DM) deemed to require early glitazone treatment and meeting Pharmac criteria for funded supply
- renal impairment (estimated glomerular filtration rate &lt; 30ml/min).
- congestive heart failure, New York Heart Association Grade 2 or higher
- clinical liver disease.
- untreated thyroid dysfunction.
- concurrent major systemic illness, including malignancy.
- metabolic bone diseases, or serum alkaline phosphatase (ALP) &gt; 2x normal limit.
- primary hyperparathyroidism.
- Bone mineral density (BMD) T score &lt; -2.0 at total hip or spine
- previous fragility fracture (forearm, humerus, hip, vertebra)
- body weight &gt;120kg

2.2.2	Medications
- use of oral glucocorticoid drugs equivalent to an average dose of prednisone = 2.5 mg/day in the preceding 12 months
- current or past use of bisphosphonate therapy
- use of hormone replacement therapy within the last 12 months
- use of other medication known to alter bone metabolism
- current use of thiazolidinediones
	
Insulin use is not an exclusion criterion, but insulin dose should be stable (+/- 20%) for 3 months before enrolment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is concealed. Allocation involves contacting the holder of the allocation schedule who is "off-site"</concealment>
    <sequence>Randomization will be undertaken using a variable block size schedule, based on computer-generated random numbers, stratified for age, menopausal status, and gender.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>This is a 1 year randomized interventional protocol, with a 1 year observational follow-up period</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/10/2008</anticipatedstartdate>
    <actualstartdate>1/10/2008</actualstartdate>
    <anticipatedenddate>30/04/2011</anticipatedenddate>
    <actualenddate>30/04/2011</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>86</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/04/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Andrew Grey</primarysponsorname>
    <primarysponsoraddress>Department of Medicine
University of Auckland
Private bag 92019
Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541
Wellesley St
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Auckland</sponsorname>
      <sponsoraddress>Private Bag 92019
Auckland</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Type 2 diabetes mellitus (T2DM) is a common disease that is associated with an increased risk of bone fracture. Recent evidence suggests that pioglitazone, a drug commonly used to treat T2DM by improving the effectiveness of action of the hormone insulin, may increase the risk of bone fracture, by decreasing the activity of bone-forming cells and thereby bone density. At present, little is known about the actions of pioglitazone on bone in humans. Our study is designed to determine the mechanism, magnitude and reversibility of the effects of pioglitazone on blood markers of bone metabolism and bone density in subjects with T2DM. Some evidence suggests that pioglitazone may increase the risk of heart failure, although it may also decrease the risk of heart attack and stroke. We intend to perform blood and ultrasound measurements of heart function in the subjects who participate in our study.
The results of the study will assist T2DM patients and their doctors in decisions around use of pioglitazone, the need for bone and/or heart monitoring in patients taking pioglitazone, and use of treatments to prevent bone loss in patients taking pioglitazone.</summary>
    <trialwebsite />
    <publication>Grey A, Bolland M, Fenwick S, Horne A, Gamble G, Drury PL, Reid IR. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol 2014:170:255-62</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Y Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
2rd Floor, BNZ Building
354 Victoria St
PO Box 1031
Hamilton
New Zealand</ethicaddress>
      <ethicapprovaldate>4/04/2008</ethicapprovaldate>
      <hrec>NTY/07/12/128</hrec>
      <ethicsubmitdate>20/11/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Andrew Grey</name>
      <address>Department of Medicine
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>64-9-3737599, ext 84423</phone>
      <fax />
      <email>a.grey@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Anne Horne</name>
      <address>Osteoporosis Research Group
Department of Medicine
Level 3,
Support Building
Auckland City Hospital
Park Rd.,
Grafton,
Auckland</address>
      <phone>64-9-3078970</phone>
      <fax />
      <email>akosteo@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Andrew Grey</name>
      <address>Department of Medicine
University of Auckland
Private Bag 92019
Auckland
new Zealand</address>
      <phone>+6499234423</phone>
      <fax />
      <email>a.grey@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>